Takeda's ARB Enters Phase III Trials In Japan As Company Moves To Acquire U.S. Biopharmaceutical Firm IDM
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda Pharmaceutical's angiotensin receptor blocker compound TAK-536 has entered Phase III clinical trials in Japan, just as the country's largest drug maker moves to complete its tender offer for the acquisition of U.S. biotech outfit IDM Pharma
You may also be interested in...
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators
Takeda Research Investment’s Graeme Martin On Corporate Venture Capital’s Role in Developing Next-Generation Biologics: An Interview With PharmAsia News(Part 2 of 2)
Attend any industry conference these days, and a general theme arises that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage projects, could impact long-term future development of emerging biotechnologies.